The Re2O skin booster is a material made by removing cells from donated human skin and finely crushing the remaining tissue scaffold so it can be injected. This is called human acellular dermal matrix (hADM). The scaffold is made mostly of collagen and elastin. It is different from a stem-cell procedure that places living cells.
3-line summary
1. The core of Re2O is not cells, but the tissue scaffold in which collagen and elastin remain.
2. In a human trial, several skin measures were better than the comparator formulation, but that result comes from a formulation that also mixed ingredients other than Re2O.
3. In consultation, confirm the exact product name, donor management, mixed ingredients, and treatment plan.
How is Re2O made?
When cells are removed from donated dermis, an extracellular matrix (ECM) of intertwined collagen and elastin remains. Making this tissue fine enough to inject is the core of producing the Re2O raw material.
The test article analyzed by Korean researchers was made from donor skin tissue selected according to set criteria. The source was also recorded so it can be traced back to which donated tissue it came from.
Composition analysis found that most of it was collagen, and elastin was also present. Genetic material from cells remained scarcely.
According to reports, the original developer is L&C Bio and the domestic supplier is Humedix, and the two companies signed a supply agreement. L&C Bio was introduced at the time as one of two Korean companies with international-standard certification. Human tissue distributed in Korea is managed under the tissue-bank system of Korea's MFDS.
What did the human trial confirm?
The trial used different formulations on the two sides of one person's face. One side received a test formulation mixing Re2O with several ingredients; the other side received non-cross-linked hyaluronic acid (HA) for comparison.
| What was checked | What the trial observed |
|---|---|
| Skin changes | During the observation period, the test formulation containing Re2O showed better results than the comparator on skin density, elasticity, wrinkle depth, pore area, and hydration measures. |
| Reactions after treatment | No serious adverse events were reported. The mild redness and swelling that appeared settled on their own. |
| How to read the results | The trial's scale and observation period were limited. Among the authors was someone who served as an advisor to the manufacturer, and what was used in the trial was not a formulation containing Re2O alone. |
This result should therefore be read as data on the mixed formulation used in the trial as a whole. It is not data showing the effect of the Re2O ingredient alone, or ranking it against every other skin booster.
The starting material differs from PN and HA
They are all called skin boosters, but the material in the syringe is not the same. Re2O starts from donated human skin; PN and HA do not use human tissue as a raw material. In consultation, it is advisable to check the actual raw material and formulation first, rather than the name.
| Comparison criterion | Re2O | PN | HA |
|---|---|---|---|
| Starting material | hADM made by finely processing donated human skin after cell removal | Polynucleotides that make up nucleic acids | Hyaluronic acid |
| Whether it is human-tissue-derived | Human-tissue-derived, so it is subject to donor screening and tissue-bank oversight | Not human-tissue-derived | Not human-tissue-derived |
| What to check in the data | Data on the test formulation that contained Re2O | Data on the PN ingredient and on each product | Data by manufacturing method, formulation, and comparison conditions |
What should you confirm before treatment?
First confirm whether the formulation tested in the paper is the same product you would actually receive. If you note the items below before consultation, you can compare the product and the treatment plan in concrete terms.
- □ Whether the exact product name is Re2O, and who the manufacturer and supplier are
- □ Whether the raw material is hADM made by removing cells from donated human skin
- □ By what criteria donors were screened, and whether the tissue source can be confirmed
- □ Which ingredients besides Re2O go into the formulation that will actually be injected
- □ Whether the described effects and duration stay within the range observed in the study
- □ Whether there is a history that should be disclosed in advance, such as previous injection of a human-derived material
Frequently asked questions
Q1. Is Re2O a stem-cell procedure?
It is different from a stem-cell procedure. What goes into Re2O is not living cells, but the tissue scaffold left after the cells are removed.
Q2. How does Re2O differ from PN and HA?
The main difference is the source material. Re2O starts from donated human skin tissue; PN and HA do not use human tissue as a raw material.
Q3. Can redness or swelling appear after treatment?
In the human trial, mild redness and swelling were observed and settled on their own. Confirm expected reactions and precautions during the consultation before treatment.
Q4. Does it work better than other HA skin boosters?
What the trial compared was a specific non-cross-linked HA formulation. Confirmed results should therefore be read only within that comparison.
Q5. How long were the effects observed?
The researchers observed skin changes for about five months after treatment. Status after that was not measured in this study.
Results, duration, and suitability vary with individual skin condition, age, and lifestyle, and the same outcome cannot be guaranteed.
Procedures may cause temporary redness or swelling, and contraindications may apply, so please confirm these during your consultation.
This article is general information and does not replace individual medical care. Please confirm diagnosis and treatment suited to your condition during a consultation.
Sources
- International Journal of Molecular Sciences: Lee YI et al., 2026 (PMC12985180), Injectable Particulated Human Acellular Dermal Matrix Booster for Skin Restoration: An Integrated Randomized, Split-Face, Double-Blinded Clinical Trial and Preclinical Study — The test article was analyzed as about 80% collagen, 3% elastin, and 0.4% sulfated glycosaminoglycan, and residual DNA was less than 50ng per 1mg. This is the source for donor screening and traceability records under American Association of Tissue Banks (AATB) criteria, a randomized double-blind trial in 20 participants, 20-week observation results, safety observations, and the study's limitations.
- The Bio: L&C Bio signs supply agreement with Humedix for hADM ingredient ‘Elravie Re2O’ — Source for the original developer, domestic supplier, supply agreement, and AATB-certified company status
- Korean Law Information Center: Act on Safety and Management of Human Tissue, etc. — Source for Korea's human-tissue and tissue-bank management system
Related reading
Sources
- 주입형 미립화 hADM 부스터 20주 split-face 임상 (Int J Mol Sci 2026, PMC12985180)PubMed Central (International Journal of Molecular Sciences)
- 엘앤씨바이오-휴메딕스 hADM 공급 계약 보도더바이오뉴스
- 인체조직안전 및 관리 등에 관한 법률국가법령정보센터
Discuss options for your current needs
We review your current health and prior procedures before explaining appropriate options and their limits.
